| First Author | Keuschnigg J | Year | 2009 |
| Journal | Blood | Volume | 114 |
| Issue | 2 | Pages | 478-84 |
| PubMed ID | 19420356 | Mgi Jnum | J:150761 |
| Mgi Id | MGI:3851669 | Doi | 10.1182/blood-2008-11-188763 |
| Citation | Keuschnigg J, et al. (2009) The prototype endothelial marker PAL-E is a leukocyte trafficking molecule. Blood 114(2):478-84 |
| abstractText | Pathologische Anatomie Leiden-endothelium antibody has been used for more than 20 years as a marker for vascular endothelium. Despite its widespread use, the target of this antibody was only recently identified as plasmalemma vesicle-associated protein-1 (PV-1). However, no function has been identified for this molecule. Here we report that activation of human umbilical vein endothelial cells with tumor necrosis factor-alpha resulted in a remarkable redistribution of PV-1 toward the peripheral areas of the cells. Furthermore, in vitro endpoint transmigration experiments showed that transcellularly migrating lymphocytes are surrounded by rings containing PV-1 and caveolin-1. Moreover, PV-1 associates physically with vimentin. In addition, administration of anti-PV-1 antibody during capillary flow assays resulted in a significant inhibition of lymphocyte transmigration through the endothelial cell layer, whereas rolling and adhesion were unaffected. In vivo blockage of PV-1 by an antibody in acute peritonitis and air pouch model resulted in a significant decrease in the number of migrating leukocytes. Here we thus define leukocyte transendothelial migration as the first known function for PV-1. |
